MétaCan
Menu
← Back to cohort
Record W2493759960 · doi:10.1158/1538-7445.am2016-2744

Abstract 2744: Synthetic lethal killing of RAD54B-deficient cancer cells by PARP1 silencing and inhibition

2016· article· en· W2493759960 on OpenAlexaff
Erin N. McAndrew, Chloe C. Lepage, Kirk J. McManus

Bibliographic record

VenueCancer Research · 2016
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsUniversity of Manitoba
Fundersnot available
KeywordsSynthetic lethalityOlaparibPARP1Gene silencingCancerCancer researchRNA interferenceCarcinogenesisBiologyPARP inhibitorCancer cellGeneticsPoly ADP ribose polymeraseMedicineDNA repairPolymeraseGeneRNA

Abstract

fetched live from OpenAlex

Abstract Colorectal Cancer (CRC) is the second leading cause of cancer-related deaths in North America. Currently, many chemotherapeutics are non-specific and preferentially kill cancer cells based on their high proliferation rate. However, due to the lack of tumor specificity, many treatments have unwanted side effects. Accordingly, identifying novel therapeutic strategies and drug targets that better target and combat cancer are needed. To address this need, synthetic lethal (SL) approaches are now being explored in many cancer contexts. Synthetic lethality refers to the lethal combination of two independently viable mutations and functions by exploiting the aberrant genetics contained within cancer cells. RAD54B is an excellent candidate to exploit using a SL paradigm as it normally functions in homologous recombination repair (HRR) and hypomorphic expression and/or function are implicated in tumorigenesis in a wide array of cancers. We predict that RAD54B and PARP1 are SL, as BRCA1 and BRCA2, which also encode functions within HRR, are SL with PARP1. To identify PARP1 as a novel SL interactor of RAD54B, we employed an established RNAi-based screening approach along with a RAD54B isogenic CRC model. Conceptually, following PARP1 silencing, a SL interaction will result in fewer cells within the RAD54B-deficient cells relative to RAD54B-proficient controls. Accordingly, we sought to determine whether PARP1 silencing or inhibition (Olaparib or BMN673) would induce selective killing within RAD54B-deficient HCT116 cells relative to controls. As predicted, PARP1 silencing with either individual or pooled siRNA duplexes and inhibition with both Olaparib and BMN673 was associated with statistically significant decreases in the number of RAD54B-deficient cells relative to controls. To confirm the SL interaction did not occur due to de novo mutations within the RAD54B-deficient cells, dual silencing of RAD54B and PARP1 was performed within the parental line and confirmed the above findings. Finally, real-time cellular analyses were conducted and revealed the decrease in cell numbers was due to cellular cytotoxicity rather than cell cycle arrest. Collectively, these data show that RAD54B and PARP1 are SL, and identify PARP1 is a candidate lead target in CRCs harboring RAD54B defects. Citation Format: Erin N. McAndrew, Chloe C. Lepage, Kirk J. McManus. Synthetic lethal killing of RAD54B-deficient cancer cells by PARP1 silencing and inhibition. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2744.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.013

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.079
GPT teacher head0.408
Teacher spread0.329 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicPARP inhibition in cancer therapy→French-language works237,207→